121 related articles for article (PubMed ID: 27668058)
1. Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer.
Fala L
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):119-22. PubMed ID: 27668058
[No Abstract] [Full Text] [Related]
2. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK; Moore DC
J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
4. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
5. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.
Thakur MK; Wozniak AJ
Lung Cancer (Auckl); 2017; 8():13-19. PubMed ID: 28293124
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
8. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
9. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
Genova C; Socinski MA; Hozak RR; Mi G; Kurek R; Shahidi J; Paz-Ares L; Thatcher N; Rivard CJ; Varella-Garcia M; Hirsch FR
J Thorac Oncol; 2018 Feb; 13(2):228-236. PubMed ID: 29158193
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Besse B; Barlesi F; Demedts I; Fuentes Pradera J; Robinet G; Gazzah A; Soldatenkova V; Frimodt-Moller B; Kim JS; Vansteenkiste J
Lung Cancer; 2019 Nov; 137():136-143. PubMed ID: 31586771
[TBL] [Abstract][Full Text] [Related]
11. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
[TBL] [Abstract][Full Text] [Related]
12. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
Dienstmann R; Felip E
Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
[TBL] [Abstract][Full Text] [Related]
13. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.
Dienstmann R; Tabernero J
Curr Opin Investig Drugs; 2010 Dec; 11(12):1434-41. PubMed ID: 21154125
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B; Witteveen PO; Ruijter R; Giaccone G; Dontabhaktuni A; Fox F; Katz T; Youssoufian H; Zhu J; Rowinsky EK; Voest EE
Clin Cancer Res; 2010 Mar; 16(6):1915-23. PubMed ID: 20197484
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
Young K; Paz-Ares L; Thatcher N; Spigel DR; Shahidi J; Soldatenkova V; Grau G; Kurek R; Shepherd FA
Thromb Res; 2018 Jul; 167():50-56. PubMed ID: 29787943
[TBL] [Abstract][Full Text] [Related]
16. Necitumumab for non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
[TBL] [Abstract][Full Text] [Related]
17. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
19. Necitumumab in squamous non-small-cell lung cancer: how to move forward?
Garrido P; Palacios J
Ann Oncol; 2016 Aug; 27(8):1374-6. PubMed ID: 27329250
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
